BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33372952)

  • 21. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
    Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.
    Moriyama T; Metzger ML; Wu G; Nishii R; Qian M; Devidas M; Yang W; Cheng C; Cao X; Quinn E; Raimondi S; Gastier-Foster JM; Raetz E; Larsen E; Martin PL; Bowman WP; Winick N; Komada Y; Wang S; Edmonson M; Xu H; Mardis E; Fulton R; Pui CH; Mullighan C; Evans WE; Zhang J; Hunger SP; Relling MV; Nichols KE; Loh ML; Yang JJ
    Lancet Oncol; 2015 Dec; 16(16):1659-66. PubMed ID: 26522332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
    Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
    Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.
    Qian M; Cao X; Devidas M; Yang W; Cheng C; Dai Y; Carroll A; Heerema NA; Zhang H; Moriyama T; Gastier-Foster JM; Xu H; Raetz E; Larsen E; Winick N; Bowman WP; Martin PL; Mardis ER; Fulton R; Zambetti G; Borowitz M; Wood B; Nichols KE; Carroll WL; Pui CH; Mullighan CG; Evans WE; Hunger SP; Relling MV; Loh ML; Yang JJ
    J Clin Oncol; 2018 Feb; 36(6):591-599. PubMed ID: 29300620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of germline TP53 mutations and history of Li-Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey.
    Magnusson S; Gisselsson D; Wiebe T; Kristoffersson U; Borg Å; Olsson H
    Pediatr Blood Cancer; 2012 Nov; 59(5):846-53. PubMed ID: 22653678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High frequency of de novo mutations in Li-Fraumeni syndrome.
    Gonzalez KD; Buzin CH; Noltner KA; Gu D; Li W; Malkin D; Sommer SS
    J Med Genet; 2009 Oct; 46(10):689-93. PubMed ID: 19556618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Report of a bi-allelic truncating germline mutation in TP53.
    Brown NJ; Bhatia K; Teague J; White SM; Lo P; Challis J; Beshay V; Sullivan M; Malkin D; Hansford JR
    Fam Cancer; 2019 Jan; 18(1):101-104. PubMed ID: 29737433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Childhood Rhabdomyosarcoma of the Female Genital Tract: Association with Pathogenic DICER1 Variation, Clinicopathological Features, and Outcomes.
    Kebudi R; Dural O; Bay SB; Gorgun O; Onder S; Bilgic B; Yilmaz I; Iribas A; Arndt CA; Harris AK; Field A; Schultz KAP; Hill DA
    J Pediatr Adolesc Gynecol; 2021 Aug; 34(4):449-453. PubMed ID: 33484847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three germline mutations in the TP53 gene.
    Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
    Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
    Kamihara J; Rana HQ; Garber JE
    Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.
    Kim J; Gianferante M; Karyadi DM; Hartley SW; Frone MN; Luo W; Robison LL; Armstrong GT; Bhatia S; Dean M; Yeager M; Zhu B; Song L; Sampson JN; Yasui Y; Leisenring WM; Brodie SA; de Andrade KC; Fortes FP; Goldstein AM; Khincha PP; Machiela MJ; McMaster ML; Nickerson ML; Oba L; Pemov A; Pinheiro M; Rotunno M; Santiago K; Wegman-Ostrosky T; Diver WR; Teras L; Freedman ND; Hicks BD; Zhu B; Wang M; Jones K; Hutchinson AA; Dagnall C; Savage SA; Tucker MA; Chanock SJ; Morton LM; Stewart DR; Mirabello L
    JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 34308104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer.
    Sylvester DE; Chen Y; Grima N; Saletta F; Padhye B; Bennetts B; Wright D; Krivanek M; Graf N; Zhou L; Catchpoole D; Kirk J; Latchoumanin O; Qiao L; Ballinger M; Thomas D; Jamieson R; Dalla-Pozza L; Byrne JA
    Genes Chromosomes Cancer; 2022 Feb; 61(2):81-93. PubMed ID: 34687117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Germline mutations of the p53 gene].
    Frebourg T
    Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.